The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

The present invention provides a preparation method for synthesizing S-nicotine from glutarate, including: reacting nicotinate with glutarate in the presence of a base catalyst to obtain 5-carbonyl-5-(pyridin-3-yl)pentanoic acid, reacting with an amination reagent to obtain 5-oxo-5-(pyridin-3-yl)pentanamide, performing Hofmann degradation on to obtain 4-amino-1-(pyridin-3-yl)butanone, reducing a carbonyl group of the 4-amino-1-(pyridin-3-yl)butanone by using (+)-B-diisopinocampheyl chloroborane to obtain (S)-4-amino-1-(pyridin-3-yl)butan-1-ol, performing chlorination and cyclization to obtain S-demethylnicotine, and finally performing amine methylation to obtain S-nicotine.

The present invention provides a preparation method for synthesizing S-nicotine from glutarate, including: reacting nicotinate with glutarate in the presence of a base catalyst to obtain 5-carbonyl-5-(pyridin-3-yl)pentanoic acid, reacting with an amination reagent to obtain 5-oxo-5-(pyridin-3-yl)pentanamide, performing Hofmann degradation on to obtain 4-amino-1-(pyridin-3-yl)butanone, reducing a carbonyl group of the 4-amino-1-(pyridin-3-yl)butanone by using (+)-B-diisopinocampheyl chloroborane to obtain (S)-4-amino-1-(pyridin-3-yl)butan-1-ol, performing chlorination and cyclization to obtain S-demethylnicotine, and finally performing amine methylation to obtain S-nicotine.

The present invention relates to nitro-vinyl-pyrazole compounds of formula (B) ##STR00001##
wherein ring A, R.sup.B2 and R.sup.B3 are as defined in claim 1, as well as the manufacture of such compounds and their subsequent use in the production of agrochemicals and/or pharmaceuticals.

The present invention relates to nitro-vinyl-pyrazole compounds of formula (B) ##STR00001##
wherein ring A, R.sup.B2 and R.sup.B3 are as defined in claim 1, as well as the manufacture of such compounds and their subsequent use in the production of agrochemicals and/or pharmaceuticals.

There are provided new inhibitors of MDM2. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by MDM2 over-expression or malfunction.

There are provided new inhibitors of MDM2. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by MDM2 over-expression or malfunction.

The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.